+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Keloids - Pipeline Review, H2 2019

  • ID: 4901371
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 55 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Allianz Pharmascience Ltd
  • FBM Therapeutics LLC
  • FirstString Research Inc
  • Lemonex Inc
  • Miragen Therapeutics Inc
  • Next Science Ltd
  • MORE
Keloids - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Keloids - Pipeline Review, H2 2019, provides an overview of the Keloids (Dermatology) pipeline landscape.

Keloids are a growth of extra scar tissue where the skin has healed after an injury. Symptoms include flesh-colored, red, or pink, lumpy (nodular) or ridged, irritated from friction such as rubbing on clothing and tender and itchy. Risk factors include age and family history. Treatment includes corticosteroid, radiation, surgical removal and silicone gel or patches.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Keloids - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Keloids (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Keloids (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Keloids and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Unknown stages are 3, 1, 5 and 1 respectively.

Keloids (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Keloids (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Keloids (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Keloids (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Keloids (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Keloids (Dermatology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Keloids (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Keloids (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Allianz Pharmascience Ltd
  • FBM Therapeutics LLC
  • FirstString Research Inc
  • Lemonex Inc
  • Miragen Therapeutics Inc
  • Next Science Ltd
  • MORE
Introduction
Report Coverage
Keloids - Overview
Keloids - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Keloids - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Keloids - Companies Involved in Therapeutics Development
Allianz Pharmascience Ltd
FBM Therapeutics LLC
FirstString Research Inc
Lemonex Inc
Miragen Therapeutics Inc
Next Science Ltd
Phio Pharmaceuticals Corp
Topadur Pharma AG
Tumorend LLC
Yuhan Corp
Keloids - Drug Profiles
Keloids - Dormant Projects
Keloids - Discontinued Products
Keloids - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Keloids, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Keloids - Pipeline by Allianz Pharmascience Ltd, H2 2019
Keloids - Pipeline by FBM Therapeutics LLC, H2 2019
Keloids - Pipeline by FirstString Research Inc, H2 2019
Keloids - Pipeline by Lemonex Inc, H2 2019
Keloids - Pipeline by Miragen Therapeutics Inc, H2 2019
Keloids - Pipeline by Next Science Ltd, H2 2019
Keloids - Pipeline by Phio Pharmaceuticals Corp, H2 2019
Keloids - Pipeline by Topadur Pharma AG, H2 2019
Keloids - Pipeline by Tumorend LLC, H2 2019
Keloids - Pipeline by Yuhan Corp, H2 2019
Keloids - Dormant Projects, H2 2019
Keloids - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Keloids, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Allianz Pharmascience Ltd
  • FBM Therapeutics LLC
  • FirstString Research Inc
  • Lemonex Inc
  • Miragen Therapeutics Inc
  • Next Science Ltd
  • Phio Pharmaceuticals Corp
  • Topadur Pharma AG
  • Tumorend LLC
  • Yuhan Corp
Note: Product cover images may vary from those shown
Adroll
adroll